TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: postoperative pain and discomfort
Endpoint domain: Adverse events/effects
Primary endpoint: Plasma oxytocin concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: maximal plasma cobalamin concentration (Cmax)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: time to reach maximal plasma cobalamin concentration (t[max])
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Annual rate of decline in forced vital capacity (FVC)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Change in synovium thickness
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pain free status
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in audience opinion
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: SNAP‐IV and IVA‐CPT scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Identification of sentinel lymph nodes (SLN)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: voiding symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Vertical dimension of occlusion
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Calcium supplement dosage
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Risk of PDD
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: overall physical activity level
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rates of cancer screenings
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Self-reported health outcomes
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Prevalence of undiagnosed congenital heart disease (CHD)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Presence of valvular regurgitation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: maximal rate of pressure development
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: clinically significant SpO2 decline
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: ever smoking
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: CVA (standing position)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: NPRS
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Increased energy expenditure
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Overall Survival - Time to Treatment Failure (OS-TTF)
Endpoint domain: Mortality/survival
Primary endpoint: IOL tilt
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in recall
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Mean transfer
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Change in mental models
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Mean AOFAS Midfoot score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Postoperative level of activities as a percentage of preinjury level
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: short-term quality-of-life outcomes
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: leg-press total load volume
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: rate of clinical success
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: microbiologic success rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: return to the ED or hospital admission by 30 days
Endpoint domain: Mortality/survival
Primary endpoint: FXIIa levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Rise in plasma AVP
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Exacerbations requiring rescue oral corticosteroids
Endpoint domain: Adverse events/effects
Primary endpoint: Change in serum phosphorus level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Protection against Exercise-Induced Bronchoconstriction (EIB)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Type of surgery (mastectomy vs BCS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Improvements in OCD symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvements in MDD symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Viable tissue of the wound
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean 24-h sputum volume
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Mean SGRQ total score
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Lung function stabilization
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Tibial bone speed of sound decrease
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: PetCO2 levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Glucose tolerance test periodicity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Need for additional glaucoma surgeries
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: wmFEV1 difference post-allergen challenge
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Rate of good response
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Symptom-free period after treatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: H pylori eradication rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: healing rate of PU
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: recurrence rate of PU
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: percent predicted forced expiratory volume in 1 second
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Mild or moderate adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: BTH1677 serum concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Clearance, serum elimination half‐life (t1/2) and volume of distribution (Vss)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: surgical success rates
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: serious adverse event rates
Endpoint domain: Adverse events/effects
Primary endpoint: urinary scores improvements
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Compliance with ischemic stroke quality indicators
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Satisfaction of discharge needs
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Nurse evaluation of preparation
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Self-evaluation of preparation
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: mean body weight gains
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Sustained plasma concentration of SFP
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percutaneous absorption ratio of SFP
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: SFP concentrations in synovial tissue and fluid
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reported drowsiness
Endpoint domain: Adverse events/effects
Primary endpoint: Dizziness
Endpoint domain: Adverse events/effects
Primary endpoint: Dystonia
Endpoint domain: Adverse events/effects
Primary endpoint: daily rhinitis scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: symptom-free days
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: visual analog scale scores for immediate improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Bayley's MDI at 1 year
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Bayley's MDI at 2 years
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean bioavailability (F)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 2-year all-cause mortality
Endpoint domain: Mortality/survival
Primary endpoint: 2-year death or major stroke
Endpoint domain: Mortality/survival
Primary endpoint: Incidence of post-ERCP pancreatitis (PEP)
Endpoint domain: Adverse events/effects
Primary endpoint: CAP-related symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: BACS composite score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cognitive functioning
Primary endpoint: chewing
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: headache-day frequency
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of days engaged in diet and diabetes self-care activities
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Readmission for DRG 127
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Sensitivity of SPECT
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Specificity of SPECT
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in HVPG
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Frequency of prolonged desaturation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AUDIT total score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: mean lag time
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: mean propagation rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Risk of hip osteoarthritis (OA)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Rate of reoperation within 3 months
Endpoint domain: Adverse events/effects
Primary endpoint: Sperm counts
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AR to ionophore challenge score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: maximum total point motion
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: one-year mortality (any cause)
Endpoint domain: Mortality/survival
Primary endpoint: target lesion area
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: target lesion volume
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Satisfaction with husband/partner companionship during labor
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Natural killer cell cytolytic activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: V95% (fraction of PTV1 receiving more than 95% of the prescribed dose)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Dmax within PTV1
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Spinal cord Dmax
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Decrease in DOB values
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Rate of tumor downstaging
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Total and abdominal fat
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: reducing symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: degree of discomfort
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Serum CRP levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: fistula recurrence rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: peer adjustment and social skills improvement
Endpoint domain: Life impact
Endpoint subdomain: Social functioning
Primary endpoint: Reduction in pro-inflammatory markers IL-6
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Reduction in pro-inflammatory markers IL-8
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Diminished NOx levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: reduction in biomarkers of endothelial dysfunction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: survival at 6 months
Endpoint domain: Mortality/survival
Primary endpoint: communication and socialization skills
Endpoint domain: Life impact
Endpoint subdomain: Social functioning
Primary endpoint: platelet aggregation rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: time for the maximal aggregation rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: urine TXB(2) in pg/mL
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: P2Y12 inhibition at first balloon inflation time
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Number of apheresis sessions
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: LDL Cholesterol
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: HDL Cholesterol
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Achieving remission in mild-to-moderately active UC
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to first resolution of symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Amplitude of delta sources
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Clinical Dementia Rating (CDR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Cardiac events (cardiac death, urgent target vessel revascularization, nonfatal myocardial infarction)
Endpoint domain: Mortality/survival
Primary endpoint: Noncardiac events (noncardiac death, stroke, severe peripheral vascular or hemorrhagic events)
Endpoint domain: Adverse events/effects
Primary endpoint: posterolateral reaching distance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: PL activation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: self-reported ankle instability severity
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Viral suppression (<50 copies/ml)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean changes in trunk‐to‐limb fat ratio
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of grade 3‐4 treatment‐related clinical adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Menstrual functioning
Endpoint domain: Life impact
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: Perceptions of sexual side effects
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: decrease in severity scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: serum lithium levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Locomotion velocity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Lumbar force
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Remission of insomnia disorder
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to remission of insomnia disorder
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Caesarean section rates
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cases of hyperstimulation
Endpoint domain: Adverse events/effects
Primary endpoint: Motor block resolution
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Clinically significant decrease in arterial pressure
Endpoint domain: Adverse events/effects
Primary endpoint: Barthel index scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rivermead mobility index scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cumulative alleviation proportion
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 6-month point prevalence abstinence
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Copeptin levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Osmolality levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Performance in modified Illinois agility test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: number of drugRCT publications per million inhabitants
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: number of citations per publication
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: national R&D expenditures by pharmaceutical companies
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Freedom from recurrent transient ischemic attack, stroke, and peripheral embolism
Endpoint domain: Mortality/survival
Primary endpoint: Right-to-left shunt abolition
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Maximal atrial septal excursion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Systemic or respiratory reaction
Endpoint domain: Adverse events/effects
Primary endpoint: diabetes knowledge
Endpoint domain: Life impact
Endpoint subdomain: null
Primary endpoint: switching rate into general anesthesia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: satisfaction rate
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Prevention of recurrent urinary tract infections
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Total number of units of blood components transfused per patient
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Percentage full thickness burn wound excised
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Pregnancy rate per started cycle
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: Development of vaccinia vesicles
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Antibody responses
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Cytotoxic T-cell responses
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Complete adenoma reversion
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Detrusor-sphincter dyssynergia episodes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: adjusted mean eGFR
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: incident CKD events
Endpoint domain: Adverse events/effects
Primary endpoint: composite of death or cardiovascular event
Endpoint domain: Mortality/survival
Primary endpoint: Color change (ΔE values)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of patients with normal alanine aminotransferase (ALT)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Liver outcomes
Primary endpoint: Percentage of patients with HBV DNA levels ≤ 10,000 copies/mL
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Percentage of patients who cleared hepatitis B surface antigen (HBsAg)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Patient satisfaction with family
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Patient satisfaction with PCP
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Patient satisfaction with medical center
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing